Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia | Zendy

Das Prabodh | Zendy; Carcao Manuel | Zendy; Hitzler Johann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia

Author(s) -

Das Prabodh,

Carcao Manuel,

Hitzler Johann

Publication year - 2006

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.20467

Subject(s) - medicine , lumbar puncture , recombinant factor viia , chemotherapy , intrathecal , fresh frozen plasma , coagulation , anesthesia , adverse effect , acute leukemia , coagulation testing , surgery , leukemia , platelet , cerebrospinal fluid

The persistence of abnormal coagulation test results after standard treatment with fresh frozen plasma (FFP) poses significant problems in children with acute leukemia requiring a diagnostic lumbar puncture and intrathecal chemotherapy. We report the prophylactic use of a single dose of 90 µg/kg recombinant activated factor VII (rFVIIa) in three children and the rapid correction of abnormal coagulation test results previously not corrected by FFP. Administration of rFVIIa was useful in avoiding a delay of diagnostic lumbar punctures and intrathecal chemotherapy. Hemorrhagic complications and adverse effects of rFVIIa were not observed. Prospective evaluation of this indication and dose appears warranted. © 2005 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research